Issue link: https://www.e-digitaleditions.com/i/1527415
26 OCTOBER 2024 Inhalation correspond to di erent rates of misclassi cation. Increasing sample size reduces uncertainty and will cause the black and blue contour lines to come closer together. As seen in Figure 4, actual true product quality must be much better than the release limits in order to maintain a viable product (e.g., with < 2% rejection rate). Expressed another way, companies should never operate at the minimum acceptable quality level but should demonstrate that every lot exceeds that level. However, the demonstration of acceptable quality (enabling consumer protection) does not necessar- ily have to be tied to rejecting product of acceptable quality (which amounts to consumer penalization). To design an appropriate PTIT for a given product, however, the entire context of the quality framework must be considered, as illustrated in Figure 3. e implementation of that quality framework is illus- trated in Figure 4, in which: • e green area represents acceptable clinical per- formance—as determined from clinical data, or as back-calculated from an external required standard, such as a pharmacopeial standard. More intense green color represents better perfor- mance. Conversely, red represents unacceptable clinical performance, with increasing red color intensity representing less acceptable performance. • e area within the blue contour line represents the population-level quality standard for true product characteristics (i.e., combinations of true batch mean and standard deviation, which are not based on sampling). is contour is determined statistically, given the clinically acceptable combi- nations of mean and standard deviation, so that the area within the blue lines is expected to pro- duce acceptable clinical outcomes. • e black contour corresponds to the demon- stration test's acceptance region (e.g., with 99% or 95% probability, allowing for uncertainty due to sampling). De ning this demonstration test, given the quality standard set by the blue lines, is straightforward, statistically. • e gap between the blue and black lines, there- fore, represents a "safety margin" to ensure that the QC-released batches are well within the range of the population product characteristics to produce acceptable clinical outcomes. • Any test based on sampling has some chance of misclassi cation, such as false acceptance (incor- rectly passing a batch), or false rejection (incor- rectly failing a batch). Blue and black lines Figure 3 Components of a Product Quality Demonstration Strategy PATIENT QUALITY REQUIREMENTS In Vivo Responses Linked to In Vitro Results Safety & Ef cacy Limits Super-potent & Sub-potent Limits PRODUCT QUALITY REQUIREMENTS CQAs Linked to In Vitro Results Regulatory Limits Quality Standard QUALITY DEMONSTRATION REQUIREMENTS Product Acceptability Linked to Quality Control Data & Process Control Data Demonstration Limits Process Control Strategy 1 2 3 Figure 4 Implementation of a Quality Framework. Green represents area of clinically acceptable performance, red represents area of clinically unacceptable performance. Blue contour refers to true population parameters set as "Quality Standard." Dashed line contour delineates area of "batch release" speci cations based on QC sampling. Population Standard Deviation Population Mean

